The combination of olaparib (Poly ADP-ribose polymerase inhibitor) with neratinib (pan-HER inhibitor) is synergistic in epithelial ovarian carcinoma overexpressing HER2.

Objective: Ovarian cancer (OC) remains the most lethal gynecologic tumor. Development of effective targeted treatments in ovarian cancer remains an unmet medical need. Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and neratinib, a pan-HER inhibitor, have recently been approved in ovarian cancer and early-stage HER2 plus breast cancer, respectively. Importantly, studies in breast cancer models showed high HER2 expression resulted in...